Free Trial
CVE:ZOM

Zomedica Pharmaceuticals Corp. (ZOM.V) (ZOM) Stock Price, News & Analysis

Zomedica Pharmaceuticals Corp. (ZOM.V) logo
C$0.28 -0.02 (-6.56%)
(As of 02/5/2020)

About Zomedica Pharmaceuticals Corp. (ZOM.V) Stock (CVE:ZOM)

Key Stats

Today's Range
C$0.29
C$0.29
50-Day Range
C$0.29
C$0.29
52-Week Range
C$0.29
C$1.50
Volume
4,800 shs
Average Volume
2,858 shs
Market Capitalization
C$36.73 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Zomedica Pharmaceuticals Corp., a development stage veterinary diagnostic and pharmaceutical company, engages in the discovery, development, and commercialization of pharmaceuticals for the companion pet. Its lead drug product candidate is ZM-007, an oral suspension formulation of metronidazole for the treatment of acute diarrhea in small dog breeds and puppies. The company is also developing ZM-012, a tablet formulation of metronidazole targeting the treatment of acute diarrhea in dogs; ZM-006, a transdermal gel formulation of methimazole targeting hyperthyroidism in cats; and ZM-011, a transdermal gel formulation of fluoxetine for the treatment of feline behavioral disorders, such as inappropriate urination. It has a collaboration agreement with Celsee Diagnostics, Inc. for the development and commercialization of liquid biopsy assays and related consumables for the detection of cancer in companion animals; and with Seraph Biosciences, Inc. for development and commercialization of novel pathogen detection system. The company was founded in 2015 and is headquartered in Ann Arbor, Michigan.

Receive ZOM Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Zomedica Pharmaceuticals Corp. (ZOM.V) and its competitors with MarketBeat's FREE daily newsletter.

ZOM Stock News Headlines

Phio Pharmaceuticals Corp.
Zomedica Corp. (ZOM) Q2 2024 Earnings Call Transcript
This Bull Market Indicator called NVDA at $116
Every now and again we find an investment idea so incredible we can’t help but share. And today is one of those rare days… Except, today we won't be giving you insight on any one particular stock… But rather, insight on a revolutionary new stock picking indicator… In fact, within the last year, this indicator has become famous for a multitude of reasons… But one of the biggest was because of the buy signal it issued on October 18th, 2022. In fact, on that very day, it said to buy NVDA at $116.37… Anyone who did would be sitting on a tremendously large return today… But even if you missed the original buy signal from October, this incredible indicator issued 11 other buy signals while Nvidia made its epic run…
Zomedica Corp Ordinary Shares ZOM
Zomedica Stock (AMEX:ZOM), Dividends
See More Headlines

ZOM Stock Analysis - Frequently Asked Questions

Zomedica Pharmaceuticals Corp. (ZOM.V)'s stock was trading at C$0.29 on January 1st, 2024. Since then, ZOM stock has increased by 0.0% and is now trading at C$0.29.
View the best growth stocks for 2024 here
.

Shares of ZOM stock and other Canadian stocks can be purchased through an online brokerage account. Popular online brokerages with access to the Canadian stock market include BMO InvestorLine, CIBC Investor's Edge, Desjardins Online Brokerage, HSBC InvestDirect, Laurentian Bank Discount Brokerage, National Bank Direct Brokerage, Qtrade Investor, Questrade, RBC Direct Investing, Scotia iTrade, TD Direct Investing, and Virtual Brokers.
Compare Top Brokerages Here.

Based on aggregate information from My MarketBeat watchlists, some other companies that Zomedica Pharmaceuticals Corp. (ZOM.V) investors own include Ocugen (OCGN), T2 Biosystems (TTOO), Meta Platforms (META), Bionano Genomics (BNGO), Onconova Therapeutics (ONTX), Biocept (BIOC) and Ford Motor (F).

Industry, Sector and Symbol

Sector
Medical
Industry
Drug Manufacturers - Specialty & Generic
Sub-Industry
Pharmaceutical Products
CIK
N/A
Fax
N/A
Employees
50
Year Founded
N/A

Profitability

Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Cash Flow
C$0.05 per share
Book Value
C$0.05 per share

Miscellaneous

Free Float
N/A
Market Cap
C$36.73 million
Optionable
Not Optionable
Beta
N/A
20 Stocks to Sell Now Cover

MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.

Get This Free Report

This page (CVE:ZOM) was last updated on 11/21/2024 by MarketBeat.com Staff
From Our Partners